GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » Beta

Arch Therapeutics (Arch Therapeutics) Beta : 6.58 (As of May. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-26), Arch Therapeutics's Beta is 6.58.


Arch Therapeutics Beta Historical Data

The historical data trend for Arch Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics Beta Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.69 -0.21 -0.73 - 1.36

Arch Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 1.28 1.36 6.43 6.28

Competitive Comparison of Arch Therapeutics's Beta

For the Biotechnology subindustry, Arch Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Beta falls into.



Arch Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Arch Therapeutics  (OTCPK:ARTH) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Arch Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Therapeutics (Arch Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Executives
Terrence W Norchi director, officer: President & CEO C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams officer: CFO and Treasurer 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen officer: Vice President, Sales C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat director
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis officer: CFO & Treasurer
Avtar S Dhillon director C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal director 100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber officer: Chief Financial Officer C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter officer: Chief Operating Officer C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616

Arch Therapeutics (Arch Therapeutics) Headlines

From GuruFocus

Arch Therapeutics Provides Corporate Update

By Marketwired Marketwired 10-13-2021